Advanced Enzyme Technologies Limited (ADVENZYMES) — regulation 31 | 5 June 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Advanced Enzyme Technologies Limited promoter Vasant Rathi disclosed on April 7, 2026, that he and related parties have not created new encumbrances on their shares during the financial year beyond previously disclosed ones, complying with SEBI Takeover Regulations Regulation 31(4).

📄 View Original Announcement (PDF)

About Advanced Enzyme Technologies Limited (ADVENZYMES)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹4,071.34 Cr P/E: 24.1 ROE: 10.3% ROCE: 13.8%

View full ADVENZYMES stock details →

📡 Get AI alerts when ADVENZYMES files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ADVENZYMES — Free

📊 More ADVENZYMES filings

See all ADVENZYMES filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ADVENZYMES files new disclosures

Track ADVENZYMES filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ADVENZYMES — Free

Free account · 2 AI queries/day